It has been well established that FLT3-ITD confers a poor prognosis due to intrinsic therapy resistance with lower complete response rates and higher relapse rates leading to inferior disease-free and overall survivals, which is particularly significant in AML with higher mutant to wild-type allelic ratio and the insertion site of ITD in the tyrosine kinase domain [4, 5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.